Biopharma Co. Hit With Suit Over Directors' 'Excessive' Pay
Law360 (November 7, 2018, 6:42 PM EST) -- Ultragenyx Pharmaceutical Inc. was hit with a derivative stockholder suit in Delaware Chancery Court on Wednesday, claiming the company's board is being paid "excessive" salaries, even as the company continues to...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
